AR TE
YEPDA
5U
99%
OF PATIENTS DID NOT PROGRESS TO AP/BC
AT 5 YEARS vs 95% WITH IMATINIB1*
*Based on Kaplan-Meier estimates of time to progression to AP or BC on core treatment (full analysis set) without clonal evolutions.
Estimated rates of no progressio